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Background: Specialty cardiovascular risk reduction clinics (CRRC) increase the proportion 
of patients attaining recommended lipid targets; however, it is not known if the beneﬁ  ts are 
sustained after discharge. We evaluated the impact of a CRRC on lipid levels and assessed the 
long-term effect of a CRRC in maintaining improved lipid levels following discharge.
Methods: The medical records of consecutive dyslipidemic patients discharged 6 months from 
a tertiary hospital CRRC from January 1991 to January 2001 were retrospectively reviewed. 
The primary outcome was the change in patients’ lipid levels between the ﬁ  nal CRRC visit 
and the most recent primary care follow-up. A worst-case analysis was conducted to evaluate 
the potential impact of the patients in whom the follow-up lipid proﬁ  les post-discharge from 
the CRRC were not obtained.
Results: Within the CRRC (median follow-up = 1.28 years in 1064 patients), we observed 
statistically signiﬁ  cant improvements in all lipid parameters. In the 411 patients for whom 
post-discharge lipid proﬁ  les were available (median follow-up = 2.41 years), there were 
no signiﬁ  cant differences observed in low-density lipoprotein-cholesterol, total cholesterol 
(TC), or triglycerides since CRRC discharge; however, there were small improvements in 
high-density lipoprotein-cholesterol (HDL-C) and TC:HDL ratio (p  0.05 for both). The 
unadjusted worst-case analysis (653 patients with no follow-up lipid proﬁ  les) demonstrated 
statistically signiﬁ  cant worsening of all lipid parameters between CRRC discharge and the most 
recent follow-up. However, when the change in lipid parameters between the baseline and the 
most recent follow-up was assessed in this analysis, the changes in all lipid parameters were 
signiﬁ  cantly improved (p  0.05).
Conclusions: This study demonstrates that a CRRC can improve lipid levels and suggests that 
these beneﬁ  ts are sustained once patients are returned to the care of their primary physician.
Keywords: cardiovascular risk factors, dyslipidemia, outcomes, pharmacotherapy, secondary 
prevention
Introduction
Cardiovascular disease (CVD) is the leading cause of death among adults worldwide 
(Murray and Lopez 1997), and in Canada it accounts for 37% of total mortality (Heart 
and Stroke Foundation of Canada 1999; Fodor et al 2000). Dyslipidemias, in particu-
lar elevated low-density lipoprotein-cholesterol (LDL-C) or decreased high-density 
lipoprotein cholesterol (HDL-C), are important risk factors for the development of 
vascular disease and recognized to be major independent risk factors for coronary 
heart disease (CHD) (Castelli et al 1986; Anderson et al 1987; Neaton et al 1992; 
Stamler et al 1996). Evidence from several large randomized controlled trials have 
demonstrated the beneﬁ  t of treating patients both with and without documented CVD 
across the spectrum of cholesterol levels with various lipid-lowering medications. 
A meta-analysis of these trials demonstrated that intervention with hydroxymethyl Vascular Health and Risk Management 2008:4(5) 1128
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glutaryl-coenzyme A reductase inhibitors (statins) showed 
a large and statistically signiﬁ  cant reduction in mortality 
from CHD (19% per mmol/L reduction in LDL-C) and 
from all-causes (12% per mmol/L reduction in LDL-C) 
(Baigent et al 2005).
On the basis of this robust cumulative evidence, expert 
groups have promulgated and regularly updated national 
guidelines to assist health care practitioners with the treat-
ment of patients with dyslipidemias (NCEP ATP III 2002; 
McPherson et al 2006). The latest updates of these guidelines 
provide a strategy to risk stratify patients according to data 
adapted from the Framingham study, based on their indi-
vidual estimated 10-year risk of experiencing a cardiac end-
point such as a nonfatal myocardial infarction or death from 
CHD (Grundy et al 1999; NCEP ATP III 2002; McPherson 
et al 2006). Despite these efforts, numerous practice-pattern 
analyses indicate that the treatment of patients is suboptimal. 
Patients are under-diagnosed, under-treated and are not 
achieving lipoprotein targets (Schrott et al 1997; Majumdar 
et al 1999; Pearson et al 2000; Garcia et al 2004; Cooke and 
Hammerash 2006; Stacy and Egger 2006).
Lipid and cardiovascular risk reduction clinics (CRRC) 
have been developed to provide assistance in the manage-
ment of patients with dyslipidemias. A number of studies 
have evaluated the effectiveness of these specialty clinics. 
Compared to management by primary care physicians or spe-
cialists in other nonlipid clinics, patients who are managed in 
CRRC or lipid clinics have lower LDL-C levels and are more 
likely to achieve their lipid targets (Shaffer and Wexler 1995; 
Harris et al 1998; Wilson et al 1999; Yates et al 2001; Gavish 
et al 2002; Koren and Hunninghake 2004; Olson et al 2005). 
Additional evidence demonstrates that patients referred to a 
CRRC were also able to achieve signiﬁ  cant improvements in 
other cardiovascular (CV) risk factors, such as blood pressure 
and glycemic control (Olson et al 2005).
While previous studies have evaluated the effectiveness 
of reducing lipid levels within the clinic itself or in compari-
son to primary care practices, to our knowledge no study has 
determined the level of lipid control for patients subsequent 
to their discharge from these clinics. This is important since 
there is uncertainty as to whether patients should be dis-
charged, at some point in their care, back to their primary care 
physician or continued to be followed in the CRRC. Clearly, 
this has signiﬁ  cant resource implications for these clinics and 
their patients. The purpose of this study was to determine the 
long-term impact on lipid control among patients who were 
initially managed in a CRRC and subsequently discharged 
to primary care follow-up.
Methods
Study design
This was a retrospective cohort study among consecutive 
patients followed within a single CRRC at the University 
of Alberta Hospital in Edmonton, Alberta, Canada. The 
Canadian health care system provides for universal access to 
essential medical and physician services. Prescription drug 
coverage is provided provincially for seniors (age 65 years) 
and the indigent; otherwise, third party drug insurance is 
paid for by individuals and/or their employers. This clinic 
utilizes a multi-factorial risk reduction model, which targets 
individualized changes in lifestyle and pharmacologic treat-
ment to decrease patients’ risk of developing or worsening 
CVD. The clinic is staffed ½ to 1 day per week by a dedicated 
multidisciplinary team of physicians (2 to 3 per clinic day), 
pharmacists, nurses, and dieticians. Together, the clinic 
team provides a comprehensive program that consists of a 
combination of education and counseling (nutrition, smoking 
cessation, and physical activity), behavioral interventions 
and pharmacotherapy, individually tailored to each patient 
to optimally reduce their CV risk proﬁ  le. In addition to in-
person follow-up for patients within the clinic, the CRRC 
also provides intermittent telephone follow-up for patients 
when necessary.
The study was reviewed and approved by the Health 
Research Ethics Board at the University of Alberta.
Patients
Our study group was comprised of consecutive patients 
referred to the CRRC for either primary or secondary pre-
vention of CVD between January 1991 and January 2001. 
Patients were identiﬁ  ed from clinic records and determined 
to be eligible for this study if they were: 18 years of age, 
had any form of dyslipidemia (elevation of any component 
of the fasting lipid proﬁ  le) at the time of referral, attended a 
minimum of one clinic visit, and had at least one follow-up 
lipid proﬁ  le reﬂ  ecting CRRC management, and had been 
discharged from the CRRC back to their primary care physi-
cian for at least 6 months. Patients were excluded from the 
study if their primary care physician refused to participate 
or failed to respond to the investigators’ repeated requests 
for study related data or the primary care physician did not 
have a follow-up lipid proﬁ  le for the patient at least 6 months 
after they were discharged from the CRRC.
Procedures
The primary care or referring physician for each patient 
fulﬁ  lling the eligibility criteria who was discharged from the Vascular Health and Risk Management 2008:4(5) 1129
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CRRC was contacted to obtain the results of the most recent 
lipid proﬁ  le. Participating physicians’ ofﬁ  ces were requested 
to fax a copy of their patients’ most recent lipid proﬁ  le report 
to the project ofﬁ  ce. In an attempt to optimize the number 
of patients included in the study, follow-up letter reminders 
to nonresponding physicians occurred in accordance to 
published criteria (Salant and Dillman 1994).
The medical records of all eligible patients were reviewed. 
The following data were abstracted: patient demographics 
(age, sex), complete fasting lipid proﬁ  les (total cholesterol 
[TC], LDL-C, HDL-C, triglycerides [TG], and TC:HDL-C 
ratio), and the number and nature of cardiac risk factors. 
Cardiac risk factors were deﬁ  ned as chart documentation by 
a physician of the following: hypertension, diabetes mellitus, 
smoking, previous myocardial infarction, percutaneous coro-
nary intervention (PCI), coronary artery bypass graft surgery 
(CABG), angina, peripheral arterial disease (PAD) (ie, end-
arterectomy or symptoms suggestive of PAD), and cerebral 
vascular disease (transient ischemic attack or stroke). Addi-
tional cardiac risk information was collected, if available, 
including the presence of electrocardiogram documented left 
ventricular hypertrophy (LVH), impaired fasting glucose or 
impaired glucose tolerance, and family history of premature 
CV disease (history of CAD in a ﬁ  rst-degree relative before 
the age of 55 years in a male or 65 years in a female). Lipid-
lowering medications prescribed during CRRC assessment 
and follow-up were also collected.
Outcome measures and statistical 
analysis
The primary outcome was the change in patients’ lipid 
levels between the ﬁ  nal CRRC visit (discharge) and the 
most recent lipid levels obtained by the patients’ physi-
cian at least 6 months after they were discharged from the 
CRRC (follow-up). The secondary outcome of interest was 
the change in patients’ lipid levels between the initial refer-
ral (baseline) and the ﬁ  nal visit to the CRRC (discharge). 
The before and after changes in the lipid parameters (TC, 
LDL, HDL, TG, and TC:HDL) were compared using gen-
eralized least squares approach. This was employed due to 
missing data and to account for the assumption of unequal 
variance-covariance over time. The least square means and 
95% conﬁ  dence interval of the differences of means with 
Tukey-Kramer adjustments for pair-wise comparisons were 
provided for each interval change in the lipid parameters. 
The descriptive demographic characteristics of all patients 
and those patients remaining in the follow-up period after 
ﬁ  nal visit to the CRRC were summarized using means for 
continuous variables and proportions for categorical variables. 
In order to evaluate the potential impact of the patients in 
whom the follow-up lipid proﬁ  les post-discharge from the 
CRRC were not obtained, a second analysis was conducted. 
The worst-case scenario was used for all patients without 
follow-up labs and their original baseline lipid values at the 
time of referral were imputed for the post-discharge follow-up 
values. Statistical signiﬁ  cance was set at a p-value of 0.05. 
All statistical analyses were performed using SAS statistical 
software (version 8.2; SAS Institute Inc. Cary, NC).
Results
Figure 1 summarizes the overall disposition of patients in 
the study. There were 1,975 patients referred to the CRRC 
between January 1991 and January 2001. From this popu-
lation, 1,064 patients (53.9%) fulﬁ  lled the study eligibility 
criteria and were evaluated within the CRRC. The reasons 
for excluding 911 patients were: age less than 18 years 
(n = 42), no diagnosis of a dyslipidemia at the time of 
referral (n = 139), no follow-up lipid proﬁ  le reﬂ  ecting the 
CRRC management (n = 269), not discharged from the 
CRRC at the time of the study or discharged for less than 
6 months (n = 415), deceased (n = 22), and medical record 
unavailable for review (n = 24). Follow-up fasting lipid 
proﬁ  les were obtained for 411 (38.6%) of the patients who 
were eligible for the study. Patient demographics for those 
with and without follow-up lipid proﬁ  les are outlined in 
Table 1.
Changes in lipid levels within the CRRC
Overall, the impact of the CRRC management was assessed in 
1064 patients (mean age = 51.9 ± 12.4 years; 41.8% female) 
followed for a median duration of 1.28 years (mean number 
of clinic visits = 3.6; mean additional follow-up contacts by 
telephone = 4.1). There were 473 (44.5%) high-risk patients, 
with a documented history of vascular disease (n = 311) or 
diabetes and age 30 years (n = 162); the median CRRC 
follow-up in this sub-group was 1.57 years (mean number 
of clinic visits = 4.5; mean additional follow-up telephone 
contacts = 5.8). The remaining 591 (55.5%) patients were 
identiﬁ  ed to have a mean of 2 cardiovascular risk factors. 
The distribution of risk factors, documented incidence of 
speciﬁ  c vascular disease, and other demographics are out-
lined in Table 1.
The CRRC achieved improvements in all lipid parameters 
(Table 2). The observed changes between the time of refer-
ral and discharge from the CRRC were decreases in LDL-C 
(19.1%), TC (17.9%), TG (40.3%), and TC:HDL (22.8%), Vascular Health and Risk Management 2008:4(5) 1130
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911 Patients Ineligible
[Age <18 (n = 42); nonlipid referral (n = 139);
no F/U lipid profile reflecting CRRC
management (n = 269); not D/C’d from
CRRC or D/C’d after <6 months F/U
(n = 415); patient deceased (n = 22); medical
records unavailable for review (n = 24)]
1,064 Patients Eligible
[470 GPs Contacted]
351 Patients Excluded
[130 Physicians Did Not
Respond]
713 Patients Included
[340 Physicians
Responded]
63 Patients Excluded
[28 Physicians Refused
Study]
650 Patients Included
[312 Physicians
Participated]
239 Patients No F/U Lipids
>6 months post-discharge
411 Patients with F/U Lipids
>6 months post-discharge
83 Patients with No F/U
Lipids since physician had
not ordered
156 Patients with No F/U Lipids
because patient died, moved or
followed by another physician
1,975 Patients Screened for
Study Eligibility
Figure 1 Flow diagram of study patient disposition.
Abbreviations:
Table 1 Patient demographics
Parameter All patients (n = 1064) Patients with follow-up (n = 411) Patients with no follow-up (n = 653)
Age (mean ± SD) 51.9 ± 12.4 52.6 ± 11.5 57.4 ± 13.0
Sex
Males 619 (58.2%) 215 (52.3%) 404 (61.9%)
Females 445 (41.8%) 196 (47.7%) 249 (38.1%)
Documented vascular disease*
Prior myocardial infarction 210 (19.7%) 75 (18.2%) 135 (20.7%)
Angina 175 (16.4%) 62 (15.1%) 113 (17.3%)
Percutaneous coronary intervention 111 (10.4%) 44 (10.7%) 67 (10.3%)
Coronary artery bypass graft surgery 118 (11.1%) 43 (10.5%) 75 (11.5%)
Transient ischemic attack 31 (2.9%) 12 (2.9%) 19 (2.9%)
Stroke 32 (3.0%) 9 (2.2%) 23 (3.5%)
Peripheral vascular disease 47 (4.4%) 11 (2.7%) 36 (5.5%)
Diabetes mellitus 162 (15.2%) 63 (15.3%) 99 (15.2%)
High risk patients (history of vascular 
disease or diabetes)
473 (44.4%) 172 (41.8%) 301 (46.1%)
(continued)Vascular Health and Risk Management 2008:4(5) 1131
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as well as an increase in HDL-C (8.9%), which were all 
statistically signiﬁ  cant (p  0.0001). These changes were 
achieved with a high frequency of lipid-lowering medication 
use (Table 3). There were a total of 1,593 lipid-lowering 
medication prescriptions in the 1,064 patients (average of 1.5 
medications/patient) used during CRRC follow-up. Statins 
were the most commonly used class of agents, with 82.7% 
of patients being prescribed one of these agents while in 
the CRRC. Fibrates were prescribed in 37.9% of patients, 
niacin in 13% and a resin in 6.1%. In addition, combination 
lipid-lowering regimens (Table 4) were utilized with a high 
frequency in this population, with 19.1% of patients being 
prescribed combination therapy at some point in time; a two-
drug combination regimen was used in 18.6% of patients and 
0.5% of patients used three-drug combination therapy. The 
most frequently prescribed combination regimen consisted of 
a statin plus a ﬁ  brate, which was used in 13.1% of patients.
Post-discharge from the CRRC
To assess the impact of lipid control after patients were 
discharged from the CRRC, complete follow-up lipid proﬁ  les 
were assessed in 411 patients. The mean age of this group 
was 52.6 ± 11.5 years; 47.7% were females and 172 (41.8%) 
were high-risk patients. The median duration between CRRC 
discharge and the most recent lipid proﬁ  le was 2.41 years. 
Compared to the total population evaluated within the CRRC, 
there were no obvious differences in these patients with regard 
to the incidence of documented vascular disease, diabetes, or 
other risk factors for CV disease (Table 1). Table 5 outlines 
differences in fasting lipid proﬁ  les between CRRC discharge 
and the most recent follow-up post-discharge. There were 
no signiﬁ  cant differences observed in LDL-C, TC, or TG. 
However, there were small, but statistically signiﬁ  cant, 
improvements in HDL-C (+0.03 mmol/L; p  0.05) and 
TC:HDL ratio (−0.20; p  0.05) observed in the most recent 
follow-up lipid proﬁ  les of these patients. Analysis of the high-
risk sub-group demonstrated no signiﬁ  cant change in any of 
the lipid parameters between discharge from the CRRC and 
the most recent follow-up.
In the worst-case analysis, the original baseline lipid 
values at the time of referral were imputed for the 653 
patients for whom follow-up labs could not be obtained, and 
Table 1. (continued)
Parameter All patients (n = 1064) Patients with follow-up (n = 411) Patients with no follow-up (n = 653)
Distribution of risk factors
Hypertension 390 (36.7%) 151 (36.7%) 239 (36.6%)
Current smoker 214 (20.1%) 80 (19.5%) 134 (20.5%)
Positive family history 642 (60.3%) 251 (61.1%) 391 (59.9%)
Left ventricular hypertrophy 29 (2.7%) 5 (1.2%) 24 (3.7%)
Other factors
Impaired fasting glucose or impaired 
glucose tolerance
69 (6.5%) 27 (6.6%) 42 (6.4%)
Solid organ transplant 47 (4.4%) 8 (1.9%) 39 (6.0%)
Number of risk factors identiﬁ  ed 
among nonhigh risk patients (mean)
22 2
Note: *not mutually exclusive.
Table 2 Change in mean lipid levels in 1,064 patients during CRRC attendance
Lipid parameter Visit 1 -(Baseline) Final visit (Discharge) Change
Mean (%) p-value
TC (mmol/L) 6.99 5.73 −1.25 (17.9) 0.0001
LDL-C (mmol/L) 4.25 3.39 −0.81 (19.1) 0.0001
HDL-C (mmol/L) 1.12 1.21 +0.10 (8.9) 0.0001
TG (mmol/L) 4.49 2.74 −1.81 (40.3) 0.0001
TC:HDL 6.44 5.03 −1.47(22.8) 0.0001
Notes: Median duration of follow-up in the CRRC (time interval between Clinic Visit 1 and Final Visit) = 1.28 years.
Abbreviation: CRRC, Cardiovascular Risk Reduction Clinic.Vascular Health and Risk Management 2008:4(5) 1132
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Table 3 Frequency of lipid-lowering medications used (at any time) during CRRC attendance
Medication Frequency (# of instances used) % Patients (n = 1064)
HMG-CoA (statin) 880 82.7
Atorvastatin 260 24.4
Pravastatin 238 22.4
Simvastatin 236 22.2
Lovastatin 76 7.1
Fluvastatin 45 4.2
Cerivastatin 25 2.3
Fibric acid derivative (ﬁ  brate) 508 37.9
Fenoﬁ  brate 386 26.4
Gemﬁ  brozil 102 9.6
Bezaﬁ  brate 20 1.9
Nicotinic acid (niacin) 138 13.0
Regular-release 104 9.8
Timed-release 34 3.2
Bile acid sequestrants (resin) 65 6.1
Cholestyramine 39 3.7
Colestipol 26 2.4
Others (Cloﬁ  brate, Salmon Oil) 2 0.2
Abbreviations: CRRC, Cardiovascular Risk Reduction Clinic; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA reductase.
Table 4 Frequency of various combination regimens used (at any time) during CRRC attendance
Combination regimen Frequency (#of Instances Used) % Patients (n = 1064)
Statin + Fibrate 139 13.1%
Statin + Niacin 25 2.4%
Statin + Resin 22 2.1%
Statin + Fish Oil 1 0.1%
Fibrate + Niacin 7 0.7%
Fibrate + Resin 2 0.2%
Niacin + Resin 2 0.2%
Statin + Niacin + Fibrate 3 0.3%
Statin + Niacin + Resin 1 0.1%
Statin + Fibrate + Resin 1 0.1%
TOTAL 203 19.1%
Abbreviation: CRRC, Cardiovascular Risk Reduction Clinic.
this data was combined with that for the 411 patients with 
follow-up lipid values. For 414 patients (39%), no reply for 
follow-up lipid proﬁ  le results was obtained from the original 
referring physician (351 patients; 33%) or the referring phy-
sician refused to participate in the study (63 patients; 6%). 
For 239 patients (22.5%), the referring physician replied 
but was unable to provide the patient’s recent lipid proﬁ  le. 
Of these, recent lipid values were not available for 156 
patients (14.7%) because the physician no longer cared for 
the patient (died, moved, or switched physicians) and there 
were 83 patients (7.8%) still under the referring physician’s 
care in whom no recent follow-up lipid screen had been 
ordered. The 653 patients with no follow-up data were older 
and had a larger percentage of male patients compared to the 
group with follow-up data, but otherwise appeared to be simi-
lar to those patients for whom follow-up labs were available. 
The unadjusted worst-case analysis demonstrated a statisti-
cally signiﬁ  cant worsening of all lipid parameters between 
CRRC discharge and the most recent follow-up (Table 6). 
However, when the change in lipid parameters between the Vascular Health and Risk Management 2008:4(5) 1133
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Table 5 Change in mean lipid levels in 411 patients following discharge from the CRRC
Lipid parameter Visit 
1-(Baseline)
Final visit 
(Discharge)
Follow-up* Mean change (95% CI†)
Visit 1 to ﬁ  nal visit Visit 1 to follow-up Discharge to Follow-up*
TC (mmol/L) 7.13 5.81 5.77 −1.32‡ (−1.59, −1.04) −1.36‡ (−1.64, -1.07) −0.04 (−0.19, +0.1)
LDL-C (mmol/L) 4.34 3.44 3.37 −0.90‡ (−1.07, −0.73) −0.97‡ (−1.14, -0.80) −0.07 (−0.21, +0.07)
HDL-C (mmol/L) 1.13 1.24 1.27 +0.11‡ (+0.08, +0.14) +0.14‡ (+0.11, +0.17) +0.03‡ (+0.01, +0.06)
TG (mmol/L) 4.84 2.62 2.64 −2.22‡ (−3.11, −1.34) −2.20‡ (−3.11, −1.30) +0.02 (−0.20, +0.24)
TC:HDL 6.54 5.05 4.85 −1.49‡ (−1.71, −1.27) −1.69‡ (−1.95, −1.42) −0.20‡ (−0.39, 0.006)
Notes: *Median duration of follow-up since CRRC discharge = 2.41 years (minimum = 0.5 years). †Tukey-Kramer adjustment. ‡p0.05.
Abbreviations: CRRC, Cardiovascular Risk Reduction Clinic; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TC, total cholesterol; 
TG, triglycerides.
Table 6 Change in mean lipid levels in patients (n = 1064) following discharge from the CRRC by worst-case analysis
Lipid parameter Visit 1-(Baseline) Final visit (Discharge) Follow-up Mean** change (95% CI†)
Visit 1 to follow-up Discharge to follow-up
TC (mmol/L) 6.98 5.73 6.46 −0.53‡ (-0.63, -0.43) +0.72‡ (+0.58, +0.86)
LDL-C (mmol/L) 4.1 3.38 3.75 −0.39‡ (-0.46, -0.33) +0.38‡ (+0.29, +0.46)
HDL-C (mmol/L) 1.11 1.21 1.17 +0.06‡ (+0.04, +0.07) −0.04‡ (−0.06, − 0.02)
TG (mmol/L) 4.53 2.73 3.70 −0.83‡ (-1.12, -0.54) +0.97‡ (+0.68, +1.25)
TC:HDL 6.45 5.04 5.79 −0.67‡ (-0.77, -0.57) +0.75‡ (+0.61, +0.89)
Notes: *411 patients had follow-up information and the follow-up lipid values of the remaining 653 patients were imputed from their initial lipid values (baseline at the time of 
clinic referral); **Means are least square means and differences in least square means estimates using generalized least squares approach; †Tukey-Kramer adjustment; ‡p  0.05
Abbreviations: CRRC, Cardiovascular Risk Reduction Clinic; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TC, total cholesterol; 
TG, triglycerides.
baseline (visit 1) and the most recent follow-up was assessed 
in this analysis, the reductions in TC (−0.53 mmo/L), LDL-C 
(−0.39mmol/L), TG (−0.83 mmol/L), and TC:HDL ratio 
(−0.67) and the increase in HDL (+0.06 mmol/L) were all 
statistically signiﬁ  cant (p  0.05).
Discussion
In an attempt to improve the management of dyslipidemias in 
patients with CHD or at high-risk for developing future CVD 
events, specialty clinics have been developed within many 
institutions. Studies evaluating the effectiveness of these 
specialty clinics have demonstrated signiﬁ  cant improvements 
in lowering LDL-C levels, achieving lipid targets, and reduc-
ing other cardiac risk factors compared to usual care (Shaffer 
and Wexler 1995; Harris et al 1998; Wilson et al 1999; Yates 
et al 2001; Gavish et al 2002; Koren and Hunninghake 2004; 
Olson et al 2005). While the evidence clearly demonstrates 
that specialty cardiovascular risk reduction or lipid clinics 
are very effective in managing patients with dyslipidemias 
and other risks for CVD, all published evaluations of these 
practices have focused on the outcomes achieved while the 
patients are managed within the clinic. The present study 
demonstrated that the improvements achieved in all lipid 
parameters during attendance at the CRRC were maintained 
in both high-risk and moderate-risk patients over a median 
follow-up of 1.28 years. During this time patients were seen 
in the clinic for a mean of 3.6 visits and received an additional 
4.1 clinic telephone contacts.
The very high frequency of medication use by the CRRC 
is one probable explanation for the signiﬁ  cant change in 
lipids observed in the patients during clinic follow-up. An 
average of 1.5 lipid-lowering medications/patient used 
during CRRC follow-up reﬂ  ects a high rate of medication 
change for efﬁ  cacy or toxicity reasons, as well as the need 
for combination therapy in many patients (19.1%). In a 
previous study within our population, we demonstrated that 
commonly prescribed combination regimens (statin + ﬁ  brate 
and statin + niacin) were safe and effective when patients are 
well informed about the potential toxicities and judiciously 
monitored (Taher et al 2002). Not surprisingly, statins 
were the class of lipid-lowering agents most commonly 
prescribed, used in 82% of our patients. In addition to Vascular Health and Risk Management 2008:4(5) 1134
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lipid-lowering therapy medication recommendations and 
adjustments, the signiﬁ  cant changes in the lipid proﬁ  les 
observed in the clinic might also be attributed to the struc-
tured, one-to-one education and counseling that patients 
received with the CRRC multidisciplinary team for dietary 
modiﬁ  cation, alcohol consumption, exercise, and smoking 
cessation during clinic follow-up.
As the primary outcome, we assessed the effectiveness 
of the CRRC in managing dyslipidemias in 1,064 patients 
over a 10-year period, demonstrating statistically signiﬁ  cant 
improvements in all lipid parameters. These improvements 
were achieved over a median of 2.41 years following last 
clinic follow-up. We successfully obtained the recent lipid 
proﬁ  les, measured 6 months after discharge from the CRRC, 
from referring primary care physicians for 39% of the eligible 
patients. The reasons for follow-up lipid proﬁ  le results not 
being obtained in the other 653 patients were provided. Inter-
estingly, there were 83 patients (7.8%) still under the referring 
physician’s care in whom no recent follow-up lipid screen 
had been ordered. The lack of follow-up lipid screening is 
surprising, since it is standard practice for the clinic physicians 
to recommend the referring physician continue to assess the 
patients’ lipid proﬁ  le every 6 to 12 months after discharge 
from the clinic. However, given the patient volume and busy 
clinical practices of most primary care physicians, some may 
have delayed ordering follow-up up lipid panels for longer 
periods of time because they or their patients had the general 
impression that the lipid proﬁ  les were already optimized.
The worst-case analysis, in which the missing follow-up 
lipid values for 653 patients were imputed, demonstrated 
that approximately 50% of the improvement in the lipid 
parameters was lost between discharge and follow-up for 
the entire study population of 1064 patients. This observa-
tion is not surprising since we imputed the original baseline 
values for 653 patients (61.4%) in this analysis; however, one 
could argue that we should have expected to have observed 
a greater loss in the beneﬁ  t in the mean lipid levels in this 
cohort following discharge, consistent with the proportion 
of patients for whom the baseline lipid values were imputed. 
This analysis demonstrated that overall change in each lipid 
parameter between the initial clinic visit and follow-up 
remained both statistically and clinically signiﬁ  cant.
Based on data from a meta-analysis by Baigent and col-
leagues (2005), the 0.97 mmol/L mean reduction in LDL-C 
that was observed in the 411 patients in whom follow-up 
lipid proﬁ  les were obtained (Table 5) would be expected to 
result in an 18.4% reduction in CHD mortality and a 11.6% 
reduction in all-cause mortality after 5 years of treatment; 
however, based on our worst-case analysis (Table 6), the 
0.39 mmol/L would be expected to reduce CHD mortality 
by 7.4% reduce all-cause mortality 4.7% after 5 years of 
treatment. Undeniably, these statistically signiﬁ  cant changes 
in lipid parameters should translate into clinically signiﬁ  cant 
improvements in patient outcomes over time.
No attempt was made in this study to determine the 
percentage of patients who successfully achieved their cho-
lesterol goals given that there were no published guidelines 
for lipid targets during the earlier years of the clinic and 
guideline recommendations at various times over the 10-year 
study period were different. This was a retrospective evalu-
ation; therefore, this study is subject to the same limitations 
as any retrospective study. However, the CRRC has been 
consistently staffed by a relatively small number of physicians 
who followed the same general charting procedures during 
the study period. In addition, the investigators utilized both 
inpatient and outpatient clinic charts to obtain the patient 
data which broadened the source of reliable documentation. 
We were unable to determine if there were other variables in 
addition to attending the CRRC, which may have inﬂ  uenced 
the sustained beneﬁ  ts that were observed in the lipid proﬁ  les 
of follow-up patients. Given the consistency in all lipid 
parameters between the ﬁ  nal in-clinic results and the most 
recent proﬁ  les following CRRC discharge, it seems logical to 
assume that both patients and referring physicians adhered to 
the recommendations implemented in the clinic; however, we 
cannot deﬁ  nitively state that there were not other factors that 
contributed to this sustained beneﬁ  t. While it was beyond the 
scope of this study to determine medication and lifestyle modi-
ﬁ  cation adherence among patients, this information would be 
helpful in determining how much of the observed long-term 
lipid improvements were the result of the CRRC management 
efforts. Finally, this study was conducted in a single clinic 
with its own unique patient referral biases, speciﬁ  c clinic 
experiences, and multidisciplinary stafﬁ  ng pattern which may 
potentially limit the generalizability of these ﬁ  ndings to other 
specialty clinic practices. The ﬁ  ndings of our study may only 
be applicable to other multidisciplinary clinics, which utilize 
a similar multifactorial risk-reduction model.
The results of this study suggest that a formally structured 
CRRC has a significant positive impact on improving 
important lipid parameters. These improvements appear to 
be sustained over the long-term after patients are discharged 
from the CRRC. This evidence lends support to the belief 
that patients can be discharged from these clinics once 
they are optimally managed, without compromising the 
improvements achieved in their CV risk proﬁ  le. Given that Vascular Health and Risk Management 2008:4(5) 1135
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the goal of specialty lipid clinics is to prevent cardiac events 
in patients with CHD or at high-risk for developing CVD in 
the future, discharging patients once they have their CV risks 
optimally managed will facilitate a greater number of patients 
being seen and beneﬁ  ting from the multidisciplinary, struc-
tured approach to risk reduction provided by such clinics.
Acknowledgments
The authors thank the following staff from the EPICORE 
(Epidemiology Coordinating and Research) Centre, Division 
of Cardiology, University of Alberta for their assistance and 
support with this study: Marilou Hervas-Malo, MSc, Sandra 
Blitz, MSc, Ruth Dupuit, BSc, Paula Priest, and Bonnie 
Woloschuk, BSN.
Disclosure
The University of Alberta CRRC was supported during the 
period of the study in part by unrestricted grants from Merck 
Frosst, Parke Davis/Pﬁ  zer, and Bristol-Myers Squibb, who 
had no inﬂ  uence on the conduct of this study. Dr. Majumdar 
is a Population Health Investigator of the Alberta Heritage 
Foundation for Medical Research and a New Investigator 
of the Canadian Institutes of Health Research. Dr. Tsuyuki 
is supported by the Merck Frosst Chair in Patient Health 
Management at the University of Alberta. Mr. Damani was 
supported by an Apotex/PACE pharmacy undergraduate stu-
dentship grant from the Association of Faculties of Pharmacy 
of Canada. Dr. Francis is a Senior Scholar of the Alberta 
Heritage Foundation for Medical Research.
References
Anderson KM, Castelli WP, Levy D. 1987. Cholesterol and mortality: 
30 years of follow up from the Framingham study. JAMA, 257:2176–80.
Baigent C, Keech A, Kearney PM, et al. 2005. Efﬁ  cacy and safety of choles-
terol-lowering treatment: prospective meta-analysis of data from 90,056 
participants in 14 randomized trials of statins. Lancet, 366:1267–78.
Castelli WP, Garrison RJ, Wilson PWF, et al. 1986. Incidence of coronary 
heart disease and lipoprotein cholesterol levels. JAMA, 256:2835–8.
Cooke CE, Hammerash WJ Jr. 2006. Retrospective review of sex differ-
ences in the management of dyslipidemia in coronary heart disease: 
an analysis of patient data from a Maryland-based health maintenance 
organization. Clin Ther, 28:591–9.
Fodor JG, Frolich JJ, Genest Jr. JJG, et al. 2000. Recommendations for the 
management and treatment of dyslipidemia. CMAJ, 162:1441–7.
Garcia Ruiz FJ, Marin Ibanez A, Perez-Jiminez F, et al. 2004. Current 
lipid management and low cholesterol goal attainment in common 
daily practice in Spain. The REALITY Study. Pharmacoeconomics, 
22(Suppl 3):1–12.
Gavish D, Leibovitz E, Elly I, et al. 2002. Follow-up in a lipid clinic improves 
the management of risk factors in cardiovascular disease patients. Isr 
Med Assoc J, 4:694–7.
Grundy SM, Pasternak R, Greenland P, et al. 1999. Assessment of cardiovas-
cular risk by use of multiple-risk-factor assessment equations: a statement 
for healthcare professionals from the American Heart Association and 
the American College of Cardiology. Circulation, 100:1481–92.
Harris DE, Gipson GW, Pearson TA, et al. 1998. Lipid lowering in a 
multidisciplinary clinic compared with primary physician management. 
Am J Cardiol, 81:929–33.
Heart and Stroke Foundation of Canada. 1999. The changing face of heart 
disease and stroke in Canada 2000. Laboratory Centre for Disease 
Control, Health Canada, Statistics Canada, Canadian Institute for 
Health Information, Canadian Cardiovascular Society, Canadian Stroke 
Society, Heart Stroke Foundation of Canada; Ottawa, Canada [online]. 
Accessed on March 15, 2008. URL: http://www.hc-sc.gc.ca/hpb/lcdc/
bcrdd/hdsc2000/pdf/card2ke.pdf.
Koren MJ, Hunninghake DB. 2004. Clinical outcomes in managed-care 
patients with coronary heart disease treated aggressively in lipid-
lowering disease management clinics. J Am Coll Card, 44:1772–9.
Majumdar SR, Gurwitz JH, Soumerai SB. 1999. Undertreatment of hyper-
lipidemia in the secondary prevention of coronary artery disease. J Gen 
Intern Med, 14:711–7.
McPherson R, Frohlich J, Fodor J, et al. 2006. Canadian Cardiovascular 
Society position statement – recommendations for the diagnosis and 
treatment of dyslipidemia and prevention of cardiovascular disease. 
Can J Cardiol, 22:913–27.
Murray CJ, Lopez AD. 1997. Global mortality, disability, and the con-
tribution of risk factors: Global Burden of Disease Study. Lancet, 
349:1436–42.
[NCEP ATP III] National Cholesterol Education Program Expert Panel 
on Detection, Evaluation, and Treatment of High Blood Cholesterol 
in Adults (Adult Treatment Panel III). 2002. Third report of the 
National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol 
in Adults (Adult Treatment Panel III) ﬁ  nal report. Circulation, 
106:3143–421.
Neaton JD, Blackburn H, Jacobs D, et al. 1992. Serum cholesterol level 
and mortality ﬁ  ndings for men screened in the Multiple Risk Factor 
Intervention Trial (MRFIT). Arch Intern Med, 152:1490–500.
Olson KL, Rasmussen J, Sandhoff BG, et al. 2005. Lipid management in 
patients with coronary artery disease by a clinical pharmacy service 
in a group model health maintenance organization. Arch Intern Med, 
165:49–54.
Pearson TA, Laurora I, Chu H, et al. 2000. The lipid treatment assessment 
project (L-TAP): a multicenter survey to evaluate the percentages of 
dyslipidemic patients receiving lipid-lowering therapy and achiev-
ing low-density lipoprotein cholesterol goals. Arch Intern Med, 
160:459–67.
Salant P, Dillman D. 1994. How to conduct your own survey. New York: 
John Wiley and Sons.
Schrott HG, Bittner V, Vittinghoff E, et al. 1997. Adherence to National 
Cholesterol Education Program treatment goals in postmenopausal 
women with heart disease. The Heart Estrogen/Progestin Replacement 
Study (HERS). The HERS Research Group. JAMA, 277:1281–6.
Shaffer J, Wexler LF. 1995. Reducing low-density lipoprotein cholesterol 
levels in an ambulatory care system. Arch Intern Med, 155:2330–5.
Stacy TA, Egger A. 2006. Results of a retrospective chart review to 
determine improvement in lipid goal attainment in patients treated 
by high-volume prescribers of lipid-modifying drugs. J Manag Care 
Pharm, 12:745–51.
Stamler J, Wentworth D, Neaton J. 1996. Is relationship between serum cho-
lesterol and risk of premature death from coronary heart disease continu-
ous and graded? Findings in 356,222 primary screenees of the Multiple 
Risk Factor Intervention Trial (MRFIT). JAMA, 256:2823–7.
Taher TH, Dzavik V, Reteff EM, et al. 2002. Tolerability of statin-ﬁ  brate 
and statin-niacin combination therapy in dyslipidemic patients at high 
risk for cardiovascular events. Am J Cardiol, 89:390–4.
Wilson TW, Quest DW, Wilson M, et al. 1999. A cardiovascular risk factor 
reduction clinic. Can J Cardiol, 15:887–91.
Yates S, Annis L, Pippins J, et al. 2001. Does a lipid clinic increase 
compliance with National Cholesterol Education Program treat-
ment guidelines? Report of a case-matched control study. South 
Med J, 94:907–9.